$506 Million is the total value of Aisling Capital LLC's 12 reported holdings in Q4 2017. The portfolio turnover from Q3 2017 to Q4 2017 was 15.4% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| LOXO | Sell | LOXO ONCOLOGY INC | $289,488,000 | -25.0% | 3,438,920 | -17.9% | 57.19% | -9.8% |
| AIMT | Sell | AIMMUNE THERAPEUTICS INC. | $84,717,000 | +14.3% | 2,240,000 | -25.1% | 16.74% | +37.4% |
| VRAY | VIEWRAY INC. | $69,273,000 | +60.8% | 7,480,887 | 0.0% | 13.68% | +93.3% | |
| TRXC | Sell | TRANSENTERIX INC. | $19,086,000 | +29.1% | 9,889,352 | -4.3% | 3.77% | +55.3% |
| ENTL | ENTELLUS MED INC | $12,894,000 | +32.1% | 528,655 | 0.0% | 2.55% | +58.9% | |
| ADMA | ADMA BIOLOGICS INC | $11,582,000 | +4.2% | 3,608,171 | 0.0% | 2.29% | +25.3% | |
| CDTX | CIDARA THERAPEUTICS INC. | $6,944,000 | -16.0% | 1,021,148 | 0.0% | 1.37% | +1.0% | |
| SYRS | SYROS PHARMACEUTICALS, INC. | $4,948,000 | -33.9% | 508,565 | 0.0% | 0.98% | -20.6% | |
| AGRX | Sell | AGILE THERAPEUTICS INC | $3,510,000 | -56.4% | 1,304,933 | -27.7% | 0.69% | -47.6% |
| CMRX | CHIMERIX INC. | $2,190,000 | -11.8% | 472,943 | 0.0% | 0.43% | +6.1% | |
| PERNIX THERAPEUTICS HLDGS INCdbcv 4.250% 4/0 | $1,054,000 | +0.1% | 2,500,000 | 0.0% | 0.21% | +20.2% | ||
| PTXTQ | PERNIX THERAPEUTICS HLDGS IN | $504,000 | -23.9% | 210,000 | 0.0% | 0.10% | -8.3% | |
| ZLTQ | Exit | ZELTIQ AESTHETICS INC | $0 | – | -11,985 | -100.0% | 0.00% | – |
| ESPR | Exit | ESPERION THERAPEUTICS INC NE | $0 | – | -837,125 | -100.0% | -6.89% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-02-07
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| TRANSENTERIX INC. | 22 | Q3 2019 | 12.1% |
| CHIMERIX INC. | 21 | Q4 2018 | 19.4% |
| ADMA BIOLOGICS INC. | 20 | Q3 2019 | 35.5% |
| LOXO ONCOLOGY INC. | 18 | Q4 2018 | 80.9% |
| AIMMUNE THERAPEUTICS INC. | 17 | Q3 2019 | 68.7% |
| CIDARA THERAPEUTICS INC. | 17 | Q3 2019 | 4.1% |
| AGILE THERAPEUTICS INC. | 16 | Q1 2018 | 5.5% |
| ZELTIQ AESTHETICS INC | 14 | Q3 2017 | 16.3% |
| ESPERION THERAPEUTICS INC NE | 14 | Q3 2017 | 24.9% |
| VERSARTIS INC | 13 | Q2 2017 | 16.2% |
View Aisling Capital LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2019-11-13 |
| 13F-HR | 2019-08-08 |
| 13F-HR | 2019-05-07 |
| 13F-HR | 2019-02-11 |
| 13F-HR | 2018-11-05 |
| 13F-HR | 2018-08-13 |
| 13F-HR | 2018-05-14 |
| 13F-HR | 2018-02-07 |
| 13F-HR | 2017-11-09 |
| 13F-HR | 2017-08-14 |
View Aisling Capital LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.